

ACTIVE:
Utilizing video game
technology to quantify
function and measure
change across the lifespan



Lindsay N Alfano, PT, DPT, PCS
Natalie F Miller, PT, DPT
Megan A Iammarino, PT, DPT
Margaret E Dugan, BS
Linda P Lowes, PT, PhD

OPTA Annual Conference
April 13, 2018



Learning Objectives:

Upon completion of the course, the learner will:

- Provide at least one example of a feasible application of this type of outcome technology to PT practice in a clinical or research setting.
- Correctly explain how integrating technology into physical therapy practice advances the field and fosters interdisciplinary collaboration.
- Accurately summarize the process of relating ACTIVE scores to clinically meaningful functional outcomes.
- Describe the steps associated with the FDA Clinical Outcome Assessment Qualification Program.



About Us

- **Our Team:** Neuromuscular Physical Therapists, Center for Gene Therapy at Nationwide Children's Hospital




- **Typical Week:**
 - 25% Clinical:
 - Evaluate patients in multidisciplinary MDA, SMA, and Neuromuscular Clinics
 - 75% Research:
 - Outcome measure development
 - Perform functional assessments for children enrolled in clinical trials
 - Grant and manuscript writing
 - Training other PTs to perform specialized outcome measures



Quick Overview:

Neuromuscular Disease:
a broad term that encompasses a group of conditions which affect any part of the nerve or muscle




Gregory T C, Rehabilitation Management of Neuromuscular Disease, <http://emedicine.medscape.com/article/321397-overview>
Photo Credit: <http://www.umdnj.edu/rm/aweb/newsletter/neuron1.jpg>



Neuromuscular Disease Umbrella

Metabolic Disorders	Myopathy	Neuromuscular Junction Disorders	Neuropathy	CNS/Spinal Cord Disorders
<ul style="list-style-type: none"> Barth syndrome Leigh disease 	<ul style="list-style-type: none"> Muscular dystrophy <ul style="list-style-type: none"> DMD BMD LGMD Inflamm. myopathies <ul style="list-style-type: none"> DM PM IBM 	<ul style="list-style-type: none"> Myasthenia Gravis Congenital Myasthenia syndromes Lambert-Eaton syndrome 	<ul style="list-style-type: none"> Charcot Marie Tooth Gullain Barré Chronic Immune Demyelinating neuropathy 	<ul style="list-style-type: none"> Spinal muscular atrophy Hereditary spastic paraparesis Friedreich ataxia

Duchenne Muscular Dystrophy (DMD)




Dystrophin works to strengthen muscle fibers

- Protect from injury
- Serves as anchor between cellular cytoskeleton and extracellular matrix

Cells without dystrophin are damaged over time with repeated cycles of contract/relax

- Progressive muscle weakness



DMD cont.

Duchenne

Becker

No dystrophin

Some dystrophin

- | | |
|---|---|
| <ul style="list-style-type: none"> • Progressive muscle weakness diagnosed early • Decline in function ~7yr • Loss of ambulation ~12yr • Severe cardiomyopathy & respiratory decline • Death in 20-30s | <ul style="list-style-type: none"> • Loss of ambulation after 15 yr • Diagnosis can occur as late as the 8th decade • Milder phenotype due to partially-functional dystrophin |
|---|---|




DMD Clinical Presentation

- Increased proximal v. distal weakness
- Gower's maneuver
- Frequent falls
- Gait impairments
- Calf pseudohypertrophy; DF ROM limitation
- Increase in skills up to age 7
- Loss of ambulation around 12 years
- High risk for scoliosis once nonambulatory
- Progressive cardiomyopathy & respiratory decline



Photos courtesy of Wendy King, PT






DMD Clinical Care

Current care guidelines:

- Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy. Lancet Neurol. 2018.
 - Part 1: Diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management
 - Part 2: Respiratory, cardiac, bone health, and orthopaedic management
 - Part 3: Primary care, emergency management, psychosocial care, and transitions of care across the lifespan

NATIONWIDE CHILDREN'S
When your child needs a hospital, everything matters.



The Truth About Clinical Trials

- Required for advancements in treatments
- May not help the participant
- Initial trials are small and have strict inclusion criteria
- Many years before FDA approval- only 9.6% of drugs are approved (Nature).



2011 at Nationwide Children's Hospital

- Recruiting for a ground-breaking clinical trial studying Eteplirsen (Exondys 51) in ambulant boys with DMD
 - 12 participants 7-13 years old, must walk within 200 and 400 meters on the 6MWT



- Local family had 2 sons with DMD
 - Younger son qualified for the study
 - Older son was no longer able to walk far enough in the 6MWT



Identifying the Need



Linda Lowes, PT, PhD



Lindsay Alfano, PT, DPT, PCS


ACTIVE:

Ability Captured Through Interactive Video Evaluation



ACTIVE development


- Need for a valid & reliable measure of upper extremity function in DMD for use in both clinical and research environments
 - Continuous scale variables
 - Minimal training required
 - Consistent motivation
 - Reduce variability
 - Utility across the disease spectrum



Workspace Volume


- Quantifies the accessible area surrounding a patient
- Relevant in ambulatory & non-ambulatory patients
- Expected to relate to function as functional tasks require a discrete amount of space
 - Typing
 - Eating
 - Dressing






Phase I: Proof of Concept

Partnership with Vectorform
Software development company





- Lessons learned:
 - Our idea could work!
 - Communication across disciplines is challenging
 - Measuring velocity/fatigue consistently is difficult


 **NATIONWIDE CHILDREN'S**
When your child needs a hospital, everything matters.

Phase II: ACTIVE

Partnership with colleagues at The Ohio State University
Students working on software development as part of their curriculum

- Lessons learned
 - Boys with DMD need to be motivated to reach
 - Pros/cons of working with students


 **NATIONWIDE CHILDREN'S**
When your child needs a hospital, everything matters.

Phase III: ACTIVE

Partnership with Multivarious Games

Software development company familiar with working in the healthcare space

- Lessons learned
 - Company invested in the work
 - Patients during development is key



Phase IV: ACTIVE


Partnership with thePlan

Software development company familiar with working in the healthcare space

- Lessons learned
 - Technology is constantly evolving, need software that can be easily transferred to other platforms




ACTIVE Trial



ACTIVE score

Raw Score is reported as cubic meters of volume
ACTIVE score is scaled for age and size based on a subject's height:



$$\text{ACTIVE score} = \left(\frac{\text{raw score (m}^3\text{)}}{\text{predicted score based on height}} \right) \times 100$$

Generally: If the subject can lean while reaching he will score over 100
Poor trunk control/limited antigravity movement gives score <100



ACTIVE Completion Report


Subject ID: SMALB	Visit Date: 23-Aug-2017
Ulna Length (cm): 18	Brooke Level: 2
Diagnosis: SMA2	Age (yr): 7
Last Successful Calibration: 23-Aug-2017T04:12:38	

Trial Time (s)	Total Volume (m ³)	Scaled Score	Trunk Left (m)	Trunk Center (m)	Trunk Right (m)
70	0.321	91.74	0.065	0.173	0.102
Expected [This Trial = 0.321, Expected = 0.42]					
70	0.379	72.76	0.093	0.173	0.101


3D From Front




From Back





From Above



Evaluating the Reliability and Validity of ACTIVE




1. Concurrent Validity: ACTIVE v. Brooke




2. Criterion Validity:

ACTIVE measures upper extremity ability



3. Content Validity: how much a measure represents every single element of a construct

	Test Description	Correlation ACTIVE	Correlation Trunk
Revised Upper Limb Module	20 items: placing hands on table, picking up small items, pushing buttons, and lifting weights	$R_s = 0.92$ $P < 0.001$ $N = 22$	$R_s = 0.85$ $P < 0.001$ $N = 22$
Expanded Hammersmith Functional Motor Scale	33 items: sitting, rolling, standing, walking and climbing stairs	$R_s = 0.85$ $P < 0.001$ $N = 23$	$R_s = 0.73$ $P < 0.001$ $N = 23$




ACTIVE: Function



	Correlation (R_s)	P value
6-minute walk test	0.36	0.02
100 meter timed test	-0.54	<0.001
10 meter walk/run	-0.52	<0.001
Rise from floor	-0.35	0.006
NSAA	0.54	<0.001
PUL	0.86	0.04



ACTIVE in DMD Longitudinal




ACTIVE Scores Are Meaningful to Patients, Regulators, and Payors

Discrete quantities of WSV are required for individual functional actives


These graphs show the minimal workspace volume required for select functional activities

Increased WSV should directly improve function




ACTIVE: Trunk strength influences performance

- Ambulant boys have better trunk strength therefore they can lean and reach further.
- Non ambulant boys with the same Brooke level score lower due to decreased trunk strength and lesser ability to lean



Responsiveness to Change




Natural history suggests a decline in function over time
Treated group shows increased WSV and therefore improved function

DMD Cohort Compared to healthy age-matched peers

Age	Control	DMD
4	121.4 ± 35.9	64.0 ± 1
5	130.3 ± 30.0	108.5 ± 32.5
6	136.5 ± 33.3	140.9 ± 48.1
7	150.3 ± 37.4	120.8 ± 31.2
8	147.6 ± 24.4	130.1 ± 32.7
9	146.9 ± 29.8	95.5 ± 42.1
10	145.7 ± 28.7	93.7 ± 35.9
11	160.4 ± 32.3	98.7 ± 37.3
12	160.3 ± 31.1	97.3 ± 28.1
13	157.0 ± 25.4	69.1 ± 35.1
14	150.2 ± 19.7	61.0 ± 46.9
15	164.4 ± 37.1	72.2 ± 48.1
16	154.6 ± 15.2	19.4 ± 17.0
17	185.2 ± 15.8	18.6 ± 21.8

Only a small number of boys with DMD met or exceeded the average scaled WSV of our control group


- Identify deficit in higher functioning individuals
- Reduce ceiling effect seen with other measures



Broader Neuromuscular Cohort

ACTIVE scaled WSV declines with increasing Brooke level and compared to controls ($p < 0.001$)

- In a larger cohort, the Jonckheere-Terpstra test for trend goes beyond identifying differences between groups and supports a stronger hypothesis that scaled WSV follows a downward trend with increasing Brooke level



Characteristic of Good Outcome Measures

- Span a large range of ages and abilities
 - No functional ceiling or floor effects
 - Size/Age – Successful down to 4ish years
- Standardized Instructions
 - In game tutorial DDT
- Reliable
 - ICC = 0.96, $P < 0.001$
- Valid
- Affordable and Easy to Implement
 - Tutorial for Set up and Administration


FDA Clinical Outcome Assessment Drug Development Tool Qualification Program



What is a DDT-Qualified COA?

- The FDA certifies that the COA is a well-defined and reliable assessment of a specified concept of interest for use in adequate and well-controlled studies

- Qualification Process:



FDA Feedback

Expected feedback:

- Cross-sectional & longitudinal data
- Relationship to function/meaningfulness

Other useful feedback:


- Objectivity/motivation – standardize instructions
- Consistency; comparison to visual field tests
- Focus on one diagnosis at a time
- Evidence that patients understand the assessment



ACTIVE-mini Overview




ACTIVE-mini uses color tracking to quantify the x, y, and z coordinates of the extremities at up to 30 Hz




NATIONWIDE CHILDREN'S
When your child needs a hospital, everything matters.

ACTIVE mini vs. Traditional Outcome Measure




NATIONWIDE CHILDREN'S
When your child needs a hospital, everything matters.

Actual v Estimated Score




Translation of ACTIVE into the Clinical Setting



NATIONWIDE CHILDREN'S
When your child needs a hospital, everything matters™

Clinical Applications of ACTIVE



NATIONWIDE CHILDREN'S
When your child needs a hospital, everything matters™


ACTIVE Setup & Instructions

Equipment Needed

- Camera and Adapter
- TV or Projector
- Laptop or PC
- ACTIVE Software
- Segmometer

Space Requirements

- Minimum of 2.5 m x 2.5 m space
- Room for maximal reaching



NATIONWIDE CHILDREN'S
When your child needs a hospital, everything matters™

ACTIVE Setup & Instructions

Positioning

- Patient sits comfortably in armless chair or wheelchair
- Feet well-supported
- Remove lateral supports on wheelchair, if safe



ACTIVE Setup & Instructions

Measuring Ulnar Length

- Patient sits with right arm positioned on a table
- Elbow in 90 degrees of flexion
- Measure from posterior aspect of the olecranon process to the styloid process of the ulna
- Measure 3 times



ACTIVE Setup & Instructions

Determining Brooke Level



Score = 1: Starting with arms at the sides, the patient can abduct the arms in a full circle without shoulder or elbow flexion until hands reach overhead.



Score = 2: Can raise arms above head only by flexing the elbow (i.e. shortening the circumference of the movement) or using accessory muscles.

Score = 3: Cannot raise hands above the head but can raise a cup with 200g weight in it to mouth using both hands if necessary.

Score = 4: Can raise hands to mouth but cannot raise a cup with 200g weight in it to mouth.

Additional Brooke 4 Requirements:

- Shoulder flexion ≤ 45 degrees
- Neck/Cervical Flexion ≤ 30 degrees – watch for excess protraction
- Minimal trunk forward and/or lateral flexion (≤ 30 degrees)

Fingers must reach bottom lip with or without elbow support

Score = 5: Cannot raise hand to mouth but can use hands to hold pen or pick up pennies or a checker from table.



Let's Practice!



 **NATIONWIDE CHILDREN'S**
When your child needs a hospital, everything matters.™

Questions?



Contact Us!
614-722-6881
Lindsay.Alfano@nationwidechildrens.org
Natalie.Miller@nationwidechildrens.org
Megan.Iammarino@nationwidechildrens.org
Linda.Lowes@nationwidechildrens.org

 **NATIONWIDE CHILDREN'S**
When your child needs a hospital, everything matters.™
